- The goal of the study is to examine the short-term effects and safety of a systemic
anti-aldosterone medication, eplerenone, in a small group of patients with central
serous chorioretinopathy (CSCR).
- There is currently no standard treatment or therapy for either acute or chronic CSCR, a
potentially debilitating eye disease.
- There is evidence in both animals and humans that high blood serum corticosteroid levels
can cause or worsen CSCR or findings similar to CSCR in the choroid and retina
- Eplerenone, a mineralocorticoid receptor antagonist, has been shown to be of visual and
anatomic benefit in a small series of 4 patients with chronic CSCR, suggesting that
decreasing mineralocorticoid action in the eye may improve signs and symptoms of CSCR
- The investigators' aim is to evaluate a standardized dose of eplerenone in a controlled
prospective fashion for both acute and chronic CSCR.
- The study consists of taking a standard dose of eplerenone, 50mg once daily, for 1 month
- Over the course of the month, patients will be monitored for side effects, as well as
visual and anatomical response to the medication